Description

BSE notice informing trading members that Windlas Biotech Limited has fixed April 24, 2026 as the record date for determining shareholder eligibility for its equity shares buyback offer.

Summary

BSE Notice No. 20260420-41 informs trading members that Windlas Biotech Limited (BSE Code: 543329) has fixed April 24, 2026 as the record date to determine the entitlement and names of equity shareholders eligible to participate in its buyback offer under the Tender Offer route.

Key Points

  • Windlas Biotech Limited (BSE Code: 543329) has announced a buyback of equity shares via Tender Offer.
  • Record date fixed as April 24, 2026 for determining eligible shareholders.
  • Ex-entitlement date is also April 24, 2026.
  • Settlement number: DR-617/2026-2027.
  • Segment: Dematerialised Securities – Rolling Settlement Segment.
  • Trading members are requested to take note of the record date.

Regulatory Changes

No new regulatory changes introduced. This notice is a standard corporate action communication under existing buyback regulations.

Compliance Requirements

  • Trading members must note the record date of April 24, 2026 for Windlas Biotech Limited’s buyback offer.
  • Shareholders holding equity shares as of the record date will be eligible to participate in the buyback.
  • Members should ensure proper settlement processing under DR-617/2026-2027.

Important Dates

  • Notice Date: April 20, 2026
  • Record Date / Ex-Entitlement Date: April 24, 2026
  • Settlement Number: DR-617/2026-2027

Impact Assessment

This circular has a focused impact on shareholders of Windlas Biotech Limited (BSE: 543329). Eligible shareholders as of the record date (April 24, 2026) may tender their shares in the buyback offer. The buyback is conducted through the Tender Offer route in the Rolling Settlement Segment. Broader market impact is limited; however, existing shareholders should assess participation in the buyback based on the offer price and their investment objectives.

Impact Justification

Company-specific buyback event affecting only Windlas Biotech shareholders; medium importance as it directly impacts eligible shareholders but is limited in broader market scope.